Senior Vice President, Microbiology
Venatorx Pharmaceuticals
Disclosure(s): Biomedical Advanced Research and Development Authority (BARDA): Grant/Research Support; Venatorx Pharmaceuticals, Inc.: Grant/Research Support, Stocks/Bonds (Private Company)
Greg Moeck, PhD, Senior Vice President, Clinical Microbiology, Venatorx Pharmaceuticals oversees microbiology development for clinical stage investigational antibacterial agents including cefepime-taniborbactam and ceftibuten-ledaborbactam. He has spent 20 years in antibacterial discovery and development, focusing on identifying, characterizing, and completing clinincal development of antibacterial agents with substantial potential benefit to patients with serious infections due to pathogens that are resistant to currently available treatments.